检索结果-南通市图书馆

Zoledronic acid combined with androgendeprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naı¨ve metastatic prostate cancer patients e A propensity scoring approach

引用

Asian Journal of Urology 2016年第1期3卷 33-38页

作者： Kazuhiro Nagao Hideyasu Matsuyama Masahiro Nozawa Isao Hara Tsukasa Nishioka takahiro komura Atsunobu Esa Shigeya Uejima Masaaki Imanishi Yasunari Uekado Takatoshi Ogawa Hiroshi Kajikawa Hirotsugu Uemura Department of Urology Graduate School of MedicineYamaguchi UniversityJapan Department of Urology Kinki University Faculty of MedicineJapan Department of Urology Wakayama Medical University School of MedicineJapan Department of Urology Sakai HospitalKinki University Faculty of MedicineJapan Department of Urology Naga HospitalJapan Department of Urology NTT Osaka HospitalJapan Department of Urology National Hospital Organization Osaka Minami Medical CenterJapan Department of Urology Nara Hospital Kinki University Faculty of MedicineJapan Department of Urology Tondabayashi HospitalJapan Department of Urology Wakayama Rosai HospitalJapan Department of Urology Kainan Municipal HospitalJapan Department of Urology Izumiotsu Municipal HospitalJapan

Objective:To clarify the oncological benefit of zoledronic acid for hormone-naive metastatic prostate cancer,patient outcome of androgen deprivation therapy with zoledronic acid(ADT+Z)and androgen deprivation therapy alone(ADT)was ***:Fifty-two patients with pathologically confirmed metastatic prostate cancer were prospectively enrolled and treated with combined androgen blockade(goserelin and bicalutamide)with zoledronic acid(4 mg every 4 weeks for 24 months).A propensity score-match with logistic regression analysis was applied to select 50 pair-matched cohorts(both from ADT+Z and from historical control cohorts who had undergone ADT alone),and patient outcomes were ***:Patients with ADT+Z had significantly longer time to progression(TTP)than those with ADT(median TTP;24.2 vs.14.0 months,p=0.0092),while no significant difference of overall survival between two groups(p=0.1502).Multivariate analysis for biochemical recurrence revealed treatment with ADT was the sole independent prognostic factor(HR:1.724,95%CI:1.06-2.86,p=0.0297).Conclusion:Combination of zoledronic acid with ADT may prolong time to castration resistant prostate cancer.

关键词： Zoledronic acid Hormone-naive prostate cancer Biochemical recurrence Propensity scorematch analysis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：